Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crism TherapeuticsAMMCF 35 EV-to-EBIT is -3.87 as of Aug. 19, 2026. GuruFocus rates AMMCF with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 369 Biotechnology companies, Crism Therapeutics ranks worse than 271002.44% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Crism Therapeutics's Enterprise Value for the quarter that ended in Dec. 2025 was $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Crism Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crism Therapeutics EV-to-EBIT Related Terms
Crism Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Crism Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Crism Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crism Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crism Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Crism Therapeutics's EV-to-EBIT falls into.
Crism Therapeutics's current Enterprise Value is $9.80 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Crism Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crism Therapeutics (AMMCF) has a EV-to-EBIT of -3.87 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Crism Therapeutics and its competitors. According to the industry distribution chart, Crism Therapeutics ranks #999999 out of 369 companies in the Biotechnology industry.
Is Crism Therapeutics' EV-to-EBIT too high?
Crism Therapeutics' current EV-to-EBIT is -3.87. Based on the distribution chart, Crism Therapeutics ranks #999999 out of 369 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crism Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Crism Therapeutics' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Crism Therapeutics ranks #999999 out of 369 companies for EV-to-EBIT. This places Crism Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.95, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Crism Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crism Therapeutics's current EV-to-EBIT is -3.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (AMMCF) has a current EV-to-EBIT of -3.87. The current EV-to-EBIT is -3.87. Crism Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Crism Therapeutics (AMMCF), the current EV-to-EBIT is -3.87 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
35GF Score
Get the complete analysis for AMMCF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMMCF has been successfully added to your 
